Sonja H. Ganzevles

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Author Correction: Hallmarks of a genomically distinct subclass of head and neck cancer.

Author Correction: Hallmarks of a genomically distinct subclass of head and neck cancer.

Journal: Nature communications

Published: February 17, 2025

Richness for Tumor-Infiltrating B-Cells in the Oral Cancer Tumor Microenvironment Is a Prognostic Factor in Early-Stage Disease and Improves Outcome in Advanced-Stage Disease.

Richness for Tumor-Infiltrating B-Cells in the Oral Cancer Tumor Microenvironment Is a Prognostic Factor in Early-Stage Disease and Improves Outcome in Advanced-Stage Disease.

Journal: Cancers

Published: October 29, 2024

Immune cell topography of head and neck cancer.

Immune cell topography of head and neck cancer.

Journal: Journal for immunotherapy of cancer

Published: July 13, 2024

Secretome and immune cell attraction analysis of head and neck cancers.

Secretome and immune cell attraction analysis of head and neck cancers.

Journal: Cancer immunology, immunotherapy : CII

Published: May 14, 2024

Hallmarks of a genomically distinct subclass of head and neck cancer.

Hallmarks of a genomically distinct subclass of head and neck cancer.

Journal: Nature communications

Published: February 07, 2024

Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.

Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.

Journal: Journal for immunotherapy of cancer

Published: December 20, 2023

An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.

An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.

Journal: Molecular cancer therapeutics

Published: May 17, 2023

NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.

NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.

Journal: International journal of molecular sciences

Published: September 21, 2021

Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.

Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.

Journal: Scientific reports

Published: June 20, 2019

IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I.

IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: February 05, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026